The comparative short-term efficacy and safety of drug-coated balloon vs. drug-eluting stent for treating small-vessel coronary artery lesions in diabetic patients

PurposeThis meta-analysis aimed to explore the comparative short-term efficacy and safety of drug-coated balloon (DCB) vs. drug-eluting stent (DES) for treating small-vessel coronary artery lesions in diabetic patients.MethodsWe searched PubMed, EMBASE, the Cochrane Library, and China National Knowl...

সম্পূর্ণ বিবরণ

সংরক্ষণ করুন:
গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক: Kui Li (Author), Kaijun Cui (Author), Xuechuan Dan (Author), Jian Feng (Author), Xiaobo Pu (Author)
বিন্যাস: গ্রন্থ
প্রকাশিত: Frontiers Media S.A., 2022-10-01T00:00:00Z.
বিষয়গুলি:
অনলাইন ব্যবহার করুন:Connect to this object online.
ট্যাগগুলো: ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_1cad3da8f9e041a9b2a50476c7f5ef4a
042 |a dc 
100 1 0 |a Kui Li  |e author 
700 1 0 |a Kui Li  |e author 
700 1 0 |a Kaijun Cui  |e author 
700 1 0 |a Xuechuan Dan  |e author 
700 1 0 |a Jian Feng  |e author 
700 1 0 |a Xiaobo Pu  |e author 
245 0 0 |a The comparative short-term efficacy and safety of drug-coated balloon vs. drug-eluting stent for treating small-vessel coronary artery lesions in diabetic patients 
260 |b Frontiers Media S.A.,   |c 2022-10-01T00:00:00Z. 
500 |a 2296-2565 
500 |a 10.3389/fpubh.2022.1036766 
520 |a PurposeThis meta-analysis aimed to explore the comparative short-term efficacy and safety of drug-coated balloon (DCB) vs. drug-eluting stent (DES) for treating small-vessel coronary artery lesions in diabetic patients.MethodsWe searched PubMed, EMBASE, the Cochrane Library, and China National Knowledgement Infrastructure (CNKI) for retrieving relevant studies regarding the comparison of DCB with DES in treating small-vessel coronary artery lesions in diabetic patients until May 31, 2022. Two independent authors screened study, extracted data, and assessed methodological quality. Then, the meta-analysis was conducted using RevMan software, version 5.4.ResultsWe included 6 studies with 847 patients in this meta-analysis. Pooled results showed that DCB was associated with fewer major adverse cardiac events (MACE) [RR, 0.60; 95% confidence interval (CI), 0.39-0.93; p = 0.02], myocardial infarction (MI) (RR, 0.42; 95% CI, 0.19-0.94; p = 0.03), target lesion revascularization (TLR) (RR, 0.24; 95% CI, 0.08-0.69; p < 0.001), target vessel revascularization (TVR) (RR, 0.33; 95% CI, 0.18-0.63; p < 0.001), binary restenosis (RR, 0.27; 95% CI, 0.11-0.68; p = 0.005), and late lumen loss (LLL) [mean difference (MD), −0.31; 95% CI, −0.36 to −0.27; p < 0.001], but was comparable technique success rate, death, minimal lumen diameter (MLD), and net lumen gain (NLG) to DES. There was no difference in long-term outcomes between these two techniques.ConclusionsThis meta-analysis shows that DCB is better than DES in the short-term therapeutic efficacy and safety of small-vessel coronary artery lesions in diabetic patients. However, more studies are required to validate our findings and investigate the long-term effects and safety of DCB. 
546 |a EN 
690 |a small-vessel coronary artery 
690 |a diabetes mellitus 
690 |a drug-coated balloon 
690 |a drug-eluting stent 
690 |a meta-analysis 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n Frontiers in Public Health, Vol 10 (2022) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fpubh.2022.1036766/full 
787 0 |n https://doaj.org/toc/2296-2565 
856 4 1 |u https://doaj.org/article/1cad3da8f9e041a9b2a50476c7f5ef4a  |z Connect to this object online.